India Healthcare: Revenue Compounds, Profit Re-Bases — Read The Mix, Not The Headline
A head-analyst view weaving Aurific same-store earnings data with Q3 FY2026 management commentary, ICRA/CRISIL/Pharmarack research and the FY27 policy stack to locate where the durable profit sits — and where this year's headline misleads.
The sector is moving from a one-year profit surge to a normalised compounding base. FY2025 was exceptional — same-store PAT +45% on US generic windfalls and hospital one-offs — and FY2026p's -9% PAT is that base lapping, not demand failing. Revenue still compounds (+12% same-store, directional), margins remain rich (22.75% EBITDA, +1.6pp), and the edge sits in domestic formulations, the hospital build-out and specialty/CDMO optionality.
Generated by AI · Not investment advice. This article is generated by AI and is provided for information only. It is not investment advice or a recommendation to buy, sell, or hold any security. Consult a SEBI-registered investment adviser before acting on it.
Executive Summary
Indian healthcare is one of the steadier, more margin-rich macro sectors in our same-store panel, and FY2025 confirms it: same-store revenue grew +11%, EBITDA +20%, and the EBITDA margin rose to 22.75% (+1.6pp) — led by Pharmaceuticals & Biotechnology at 23.21% (+1.8pp). The constructive case is structural, not cyclical: resilient, price-led domestic formulations (IPM closed CY2025 at ~Rs 2.40 lakh crore on +8.1% value growth), a hospital build-out ICRA pegs at +18-20% revenue in FY27, and a widening specialty/biosimilar/CDMO mix. Directional FY2026 same-store revenue (+12% macro) sits squarely inside the external reads — ICRA/CRISIL's 7-9% sector and 9-11% for covered samples.
Members only
Continue reading with Aurific
The full note — snapshot, sector trends, evidence checklist, decision rules and watch list — is available to Aurific members. Sign in to keep reading, or request access.